Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.amjms.2016.12.013 http://scihub22266oqcxt.onion/10.1016/j.amjms.2016.12.013 C5341697!5341697!28262205     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28262205.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Am+J+Med+Sci 2017 ; 353 (3): 207-15 Nephropedia Template TP {{tp|p=28262205|t=2017. Characterization of Mast Cell Activation Syndrome |pdf=|usr=}}{{28262205}} gab.com Text Characterization of Mast Cell Activation Syndrome JO: Am J Med Sci http://www.kidney.de/pget.php?&tw=1&pmid=28262205 #FOAvip Background: Mast cell activation syndrome (MCAS), a recently recognized non-neoplastic mast cell (MC) disease driving chronic multisystem inflammation ± allergy, appears prevalent and thus important. We report the first systematic characterization of a large MCAS population. Method: Demographics, comorbidities, symptoms, family histories, and physical exam and laboratory findings were reviewed in 298 retrospective and 115 prospective MCAS patients. Blood samples from prospective subjects were examined by flow cytometry for clonal MC disease and tested for cytokines potentially driving the monocytosis frequent in MCAS. Results: Demographically, white females dominated. Median ages at symptom onset/diagnosis were 9/49 years (ranges 0?88/16?92); median time from symptom onset to diagnosis was 30 years (range 1?85). Median numbers of comorbidities/symptoms/family medical issues were 11/20/4 (ranges 1?66/2?84/0?33). Gastroesophageal reflux, fatigue, and dermatographism were the most common comorbidity, symptom, and exam finding. Abnormalities in routine labs were common and diverse but typically modest. The most useful diagnostic markers were heparin, prostaglandin D2, histamine, and chromogranin A. Flow cytometric and cytokine assessments were unhelpful. Conclusions: Our study highlights MCAS?s morbidity burden and challenging heterogeneity. Recognition is important given good survival and treatment prospects. Twit Text FOAVip Characterization of Mast Cell Activation Syndrome ????Am J Med Sci http://www.kidney.de/pget.php?&tw=1&pmid=28262205 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28262205 #FOAvip English Wikipedia <ref>{{Cite pmid|28262205}}</ref> Characterization of Mast Cell Activation Syndrome #MMPMID28262205 Afrin LB; Self S; Menk J; Lazarchick J Am J Med Sci 2017[Mar]; 353 (3): 207-15 PMID28262205show ga Background: Mast cell activation syndrome (MCAS), a recently recognized non-neoplastic mast cell (MC) disease driving chronic multisystem inflammation ± allergy, appears prevalent and thus important. We report the first systematic characterization of a large MCAS population. Method: Demographics, comorbidities, symptoms, family histories, and physical exam and laboratory findings were reviewed in 298 retrospective and 115 prospective MCAS patients. Blood samples from prospective subjects were examined by flow cytometry for clonal MC disease and tested for cytokines potentially driving the monocytosis frequent in MCAS. Results: Demographically, white females dominated. Median ages at symptom onset/diagnosis were 9/49 years (ranges 0?88/16?92); median time from symptom onset to diagnosis was 30 years (range 1?85). Median numbers of comorbidities/symptoms/family medical issues were 11/20/4 (ranges 1?66/2?84/0?33). Gastroesophageal reflux, fatigue, and dermatographism were the most common comorbidity, symptom, and exam finding. Abnormalities in routine labs were common and diverse but typically modest. The most useful diagnostic markers were heparin, prostaglandin D2, histamine, and chromogranin A. Flow cytometric and cytokine assessments were unhelpful. Conclusions: Our study highlights MCAS?s morbidity burden and challenging heterogeneity. Recognition is important given good survival and treatment prospects. äCharacterization of Mast Cell Activation Syndrome (epmc).pdf DeepDyve Pubget Overpricing